Analyst Price Targets — ELV
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 3, 2026 11:38 am | — | RBC Capital | $358.00 | $341.83 | TheFly | Elevance Health downgraded to Sector Perform from Outperform at RBC Capital |
| February 2, 2026 3:02 pm | — | Truist Financial | $390.00 | $341.29 | TheFly | Elevance Health price target lowered to $390 from $400 at Truist |
| February 2, 2026 11:58 am | — | Craig-Hallum | $409.00 | $340.68 | StreetInsider | Elevance (ELV) PT Lowered to $409 at Bernstein |
| February 2, 2026 11:58 am | — | Piper Sandler | $409.00 | $340.68 | StreetInsider | Elevance (ELV) PT Lowered to $409 at Bernstein |
| February 1, 2026 3:12 pm | — | Bernstein | $409.00 | $345.74 | TheFly | Elevance Health price target lowered to $409 from $431 at Bernstein |
| January 30, 2026 11:22 am | — | Wells Fargo | $391.00 | $346.98 | TheFly | Elevance Health price target lowered to $391 from $424 at Wells Fargo |
| January 30, 2026 10:26 am | — | Barclays | $393.00 | $346.98 | TheFly | Elevance Health price target lowered to $393 from $404 at Barclays |
| January 29, 2026 2:22 pm | — | UBS | $400.00 | $345.27 | TheFly | Elevance Health price target lowered to $400 from $425 at UBS |
| January 29, 2026 2:00 pm | — | Deutsche Bank | $332.00 | $345.22 | TheFly | Elevance Health price target raised to $332 from $320 at Deutsche Bank |
| January 29, 2026 12:29 pm | Jason Cassorla | Guggenheim | $396.00 | $341.85 | TheFly | Elevance Health price target lowered to $396 from $414 at Guggenheim |
Latest News for ELV
INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health (NYSE: ELV) and the National Diaper Bank Network (NDBN) today announced a new national pilot program designed to expand access to diapers for families with infants and young children, helping reduce financial strain while generating evidence on how meeting basic material needs can improve maternal and child health outcomes. The 12-month pilot program will provide free…
111 Capital bought a new stake in shares of Elevance Health, Inc. (NYSE: ELV) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 2,537 shares of the company's stock, valued at approximately $820,000. Several other institutional investors have also added to or
Elevance Health, Inc. (NYSE: ELV - Get Free Report) was the target of a large increase in short interest in the month of February. As of February 13th, there was short interest totaling 4,649,830 shares, an increase of 29.3% from the January 29th total of 3,595,465 shares. Approximately 2.1% of the company's shares are short sold.
SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Elevance Health, Inc. (NYSE: ELV). The investigation focuses on whether Elevance and its executive officers complied with federal securities laws.
Elevance Health stock drops after CMS freezes Medicare Advantage enrollment over compliance concerns dating to 2018.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.